Kisqali (Ribociclib) is a targeted cancer therapy used in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. Ribociclib works by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the growth of cancer cells and slowing disease progression. It’s an FDA-approved therapy shown to extend survival in hormone receptor-positive breast cancer patients.
Select options
This product has multiple variants. The options may be chosen on the product page
Lenvima (Lenvatinib) is a multi-targeted tyrosine kinase inhibitor designed to treat various forms of advanced cancer. It works by blocking multiple signaling pathways responsible for tumor growth, angiogenesis, and cancer cell survival. Lenvima is commonly prescribed for:
Differentiated thyroid cancer (DTC)
Hepatocellular carcinoma (HCC)
Advanced renal cell carcinoma (RCC)
Advanced endometrial cancer (in combination with immunotherapy)
Its oral formulation provides a powerful alternative to intravenous therapies, offering flexibility and convenience in cancer management.
Select options
This product has multiple variants. The options may be chosen on the product page
End of content
End of content
“Sign up now and unlock a special 50% discount on your first purchase!”
Subscribe to our newsletter and get the latest trending products and offers updates.
Wait! before you leave…
We have something special for you
Use above code to get 50% off for your first order when checkout. Don't miss it.
